News
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 ...
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
The lupus rash is not only a visible symptom but is also closely linked to the underlying systemic activity of lupus," said Jan Klatt, Head of Development Unit Neurology Immunology for the Healthcare ...
However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...
Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a ...
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...
The stock's fall snapped a three-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback